Role of Sodium ,
Biology of Incretins: GLP-1 and GIP, Gastroenterology, vol.132, issue.6, pp.2131-2157, 2007. ,
DOI : 10.1053/j.gastro.2007.03.054
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial, The Lancet, vol.376, issue.9739, pp.431-439, 2010. ,
DOI : 10.1016/S0140-6736(10)60590-9
DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.5, pp.1301-1310, 2011. ,
DOI : 10.1210/jc.2010-2081
La Revue de Médecine Interne, pp.379-383, 1999. ,
Insulinothérapie dans le Diabète de Type II, pp.55-65, 2004. ,
Exenatide and weight loss, Nutrition, vol.26, issue.3, pp.243-249, 2010. ,
DOI : 10.1016/j.nut.2009.07.008
Agonist) Expresses Anti-Inflammatory Properties in Cultured Human Monocytes / Macrophages in a Protein Kinase A and B / Akt Manner, Pharmacological Reports, vol.68, issue.2, pp.329-337, 2016. ,
Exenatide Once Weekly Versus Liraglutide Once Daily in Patients With Type 2 Diabetes (DURATION-6) : a Randomised, Open-Label Study. The Lancet, pp.117-124, 2013. ,
Incretins : a New Approch ; GLP-1 Receptor Singnaling : Effects on Pancreatic ?- Cell Proliferation and Survival. Diabetes and Metabolisme, pp.73-77, 2008. ,
Diabetic neuropathy: clinical manifestations and current treatments, The Lancet Neurology, vol.11, issue.6, pp.521-534, 2012. ,
DOI : 10.1016/S1474-4422(12)70065-0
Encapsulation of Exenatide in Poly-(D,L-lactide-co-glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes, Diabetes Technology and Therapeutics, vol.13, issue.11, pp.1145-1154, 2013. ,
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study, The Lancet, vol.372, issue.9645, pp.1240-1250, 2008. ,
DOI : 10.1016/S0140-6736(08)61206-4
Activité Physique et Diabète de ,
??quilibre potassique, hypokali??mie et hyperkali??mie, N??phrologie & Th??rapeutique, vol.6, issue.3, pp.180-199, 2010. ,
DOI : 10.1016/j.nephro.2010.03.004
Isolation and Characterization of Exendin-4, an Exendin-3 Analogue from Heloderma Suspectum Venom, The Journal of Biological Chemestry, vol.267, issue.11, pp.7402-7405, 1992. ,
Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial, Diabetes Care, vol.33, issue.10, pp.2217-2224, 2010. ,
DOI : 10.2337/dc10-0612
Effects of SGLT2 Inhibitors on Cardiovascular Outcomes. Diabetes and Vascular Disease Research, pp.117-123, 2012. ,
The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent, Toxicon, vol.59, issue.4, pp.464-471, 2012. ,
DOI : 10.1016/j.toxicon.2010.12.016
Les incr??tines, Nutrition Clinique et M??tabolisme, vol.22, issue.2, pp.59-65, 2008. ,
DOI : 10.1016/j.nupar.2008.04.009
D??finition, classification et diagnostic du diab??te, du pr??diab??te et du syndrome m??tabolique, Classification et Diagnostic du Diabète, du Prédiabète et du Syndrome Métabolique, pp.369-372 ,
DOI : 10.1016/j.jcjd.2013.07.031
Les Actions Physiologiques de l'Insuline. Médecine des Maladies Métaboliques, pp.124-129, 2008. ,
A Review of Newer Treatment Approaches for Type-2 Diabetes ,
Cancers du pancr??as et s??curit?? des incr??tines : ??tat des lieux en 2014, Médecine des Maladie Métaboliques, pp.380-391, 2014. ,
DOI : 10.1016/S1957-2557(14)70835-1
Avis de la Commission de Transparence, 2014. ,
Avis de la Comission de Transparence, 2015. ,
Avis de la Commission de Transparence, 2012. ,
Avis de la Commission de Transparence, Décembre, 2009. ,
Actualisation du Référentiel de Pratiques de l'Examen Périodique de Santé, Octobre 2014b, Prévention et Dépistage du Diabète de Type 2 et des Maladies Liées au Diabète ,
Effect of excipients on PLGA film degradation and the stability of an incorporated peptide, Journal of Controlled Release, vol.117, issue.3, pp.413-420, 2007. ,
DOI : 10.1016/j.jconrel.2006.11.023
Adherence to Liraglutide once daily or exenatide once weekly Over A 12-Month period among Commercially Insured Patients With Type 2 diabetes Mellitus: A retrospective observational study, Value in Health, vol.18, issue.3, 2015. ,
DOI : 10.1016/j.jval.2015.03.374
The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus, British Journal of Clinical Pharmacology, vol.42, issue.Suppl. 1, pp.432-444, 2013. ,
DOI : 10.1111/bcp.12056
Treatment of Diabètes : New Clinical Studies and Effects of GLP-1 on Macrovascular Complications. Annales d'Endocrinologie, pp.505-510, 2010. ,
Effect of water on exenatide acylation in poly(lactide-co-glycolide) microspheres, International Journal of Pharmaceutics, vol.454, issue.1, pp.344-353, 2013. ,
DOI : 10.1016/j.ijpharm.2013.07.012
Production et s??cr??tion de l'insuline par la cellule ?? pancr??atique, EMC - Endocrinologie, vol.2, issue.4 ,
DOI : 10.1016/j.emcend.2005.07.001
Prévalence du Diabète Traité Pharmacologiquement et Disparités Territoriales en France en 2012 Bulletin Epidémiologique Hebdomadaire, Numéro 30-31, Novembre 2014, Pages 493-499 Diabète : des disparités sociales et territoriales importantes, Bull Epidémiol Hebd, pp.30-3149230, 2014. ,
Structural and molecular conservation of glucagon-like peptide-1 and its receptor confers selective ligandreceptor interaction, Frontiers in Endocrinology, vol.141, issue.3, 2012. ,
Effects of Incretin Hormones on ??-Cell Mass and Function, Body Weight, and Hepatic and Myocardial Function, The American Journal of Medicine, vol.123, issue.3, pp.19-27, 2010. ,
DOI : 10.1016/j.amjmed.2009.12.006
Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes, Regulatory Peptides, vol.117, issue.2, pp.77-88, 2004. ,
DOI : 10.1016/j.regpep.2003.10.028
Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes, American Journal of Health-System Pharmacy, vol.70, issue.4, pp.311-319, 2013. ,
DOI : 10.2146/ajhp110514
Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With a Thiazolidinedione Alone or in Combination With Metformin for 2 Years, Clinical Therapeutics, vol.34, issue.10, 2012. ,
DOI : 10.1016/j.clinthera.2012.09.007
Complications Métaboliques Aigües du Diabète. Réanimation, pp.761-767, 2008. ,
Dapagliflozin: a review on efficacy, clinical effectiveness and safety, Expert Opinion on Investigational Drugs, vol.11, issue.1, pp.131-140, 2013. ,
DOI : 10.1001/jama.241.19.2035
Glucose Transporters in Human Renal Proximal Tubular Cells Isolated From the Urine of Patients With Non-Insulin-Dependent Diabetes, Diabetes, vol.54, issue.12, pp.3427-3434, 2005. ,
DOI : 10.2337/diabetes.54.12.3427
Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus, Diabetes/Metabolism Research and Reviews, vol.60, issue.5, pp.347-356, 2013. ,
DOI : 10.1002/dmrr.2403
Sitagliptin Used as Monotherapy in Drug-Naive Patients with Type ,
Base des Médicaments et Informations Tarifaires, Assurance Maladie en ,
Diabetes, Hyperglycemia, and Infections, Best Practice & Research Clinical Anaesthesiology, vol.22, issue.3, pp.519-535, 2008. ,
DOI : 10.1016/j.bpa.2008.06.005
Inflammation in Diabetic Retinopathy Progress in Retinal and Eye Research, pp.343-358, 2011. ,
Base de données des prescripteurs en ligne, 2016. ,
Allergie à l'Insuline : Mise au Point!. Revue Française d'Allergologie, pp.336-342, 2011. ,
Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin, Annals of Internal Medicine, vol.156, issue.6, pp.405-415, 2012. ,
DOI : 10.7326/0003-4819-156-6-201203200-00003
Smug Mug, 2007. ,
Five-Year Efficacy and Safety Data of Exenatide Once Weekly, Mayo Clinic Proceedings, vol.90, issue.3 ,
DOI : 10.1016/j.mayocp.2015.01.008
Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation, Clinical Therapeutics, vol.38, issue.1, pp.149-160, 2016. ,
DOI : 10.1016/j.clinthera.2015.11.017
Molecular Mechanisms Linking Diabetes to the Accelerated Development of??Atherosclerosis, Canadian Journal of Diabetes, vol.37, issue.5, pp.345-380, 2013. ,
DOI : 10.1016/j.jcjd.2013.06.001